Helixmith Co., Ltd (KOSDAQ:084990)

Market Cap	404.29B +285.1%
Revenue (ttm)	2.60B -47.8%
Net Income	-434.92M
EPS	-9.00
Shares Out	46.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	628,135
Average Volume	952,459
Open	8,830.00
Previous Close	8,780.00
Day's Range	8,830.00 - 9,460.00
52-Week Range	2,115.00 - 9,850.00
Beta	0.72
RSI	63.42
Earnings Date	Apr 2, 2026

About Helixmith

Helixmith Co., Ltd develops biologic and natural nutraceutical products. The company offers LAYLA Tab for osteoarthritis; Allex and Allex i for hypersensitivity improvement; and Mnemosyne for memory improvement. Its lead gene therapy product is Engensis (VM202), which is in a phase III clinical trial for diabetic peripheral neuropathy and diabetic foot ulcer; a phase II clinical trial for amyotrophic lateral sclerosis (ALS) and claudication; and a phase I clinical trial for charcot-marie-tooth disease and coronary artery disease. The company al...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 38
• Stock Exchange: KOSDAQ
• Ticker Symbol: 084990

Financial Performance

In 2025, Helixmith's revenue was 2.60 billion, a decrease of -47.77% compared to the previous year's 4.97 billion. Losses were -434.92 million, -97.19% less than in 2024.